CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 50,000 Shares

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 50,000 shares of the company’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $15.13, for a total transaction of $756,500.00. Following the sale, the chief executive officer directly owned 798,135 shares of the company’s stock, valued at approximately $12,075,782.55. This represents a 5.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

CeriBell Stock Performance

CeriBell stock traded up $1.34 on Tuesday, reaching $17.35. 679,211 shares of the stock were exchanged, compared to its average volume of 297,570. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $32.75. The firm has a fifty day moving average price of $12.42 and a two-hundred day moving average price of $14.34. The stock has a market cap of $643.69 million and a PE ratio of -11.49.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. CenterBook Partners LP acquired a new position in shares of CeriBell in the 1st quarter worth approximately $3,531,000. New York State Common Retirement Fund acquired a new stake in CeriBell in the 1st quarter valued at $67,000. Lord Abbett & CO. LLC grew its position in CeriBell by 7.9% in the first quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company’s stock valued at $6,138,000 after acquiring an additional 23,451 shares during the period. Swiss National Bank bought a new position in shares of CeriBell during the first quarter valued at $467,000. Finally, Federated Hermes Inc. boosted its stake in shares of CeriBell by 111.3% in the 1st quarter. Federated Hermes Inc. now owns 786,751 shares of the company’s stock valued at $15,113,000 after purchasing an additional 414,500 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CBLL. Raymond James Financial began coverage on CeriBell in a research report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. TD Cowen dropped their price objective on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. reduced their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.17.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.